Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance

BACKGROUND: (i).. Identify and map core outcome sets (COS), across 11 immune-mediated inflammatory diseases (IMIDs) in order to facilitate the selection of relevant outcomes across the conditions for innovative trials of tissue-agnostic drug therapies. (ii).. Compare outcomes or endpoints recommende...

Descripción completa

Detalles Bibliográficos
Autores principales: Aiyegbusi, Olalekan Lee, di Ruffano, Lavinia Ferrante, Retzer, Ameeta, Newsome, Philip N., Buckley, Christopher D., Calvert, Melanie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761289/
https://www.ncbi.nlm.nih.gov/pubmed/35033186
http://dx.doi.org/10.1186/s13063-022-06000-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761289/
https://www.ncbi.nlm.nih.gov/pubmed/35033186
http://dx.doi.org/10.1186/s13063-022-06000-w

Ejemplares similares